tetano
Editor, Senior Moderator
J Paediatr Child Health. 2016 Sep 4. doi: 10.1111/jpc.13313. [Epub ahead of print]
[h=1]Influenza vaccine efficacy in young children attending childcare: A randomised controlled trial.[/h] Li-Kim-Moy JP[SUP]1,[/SUP][SUP]2[/SUP], Yin JK[SUP]1,[/SUP][SUP]2[/SUP], Heron L[SUP]1,[/SUP][SUP]2[/SUP], Leask J[SUP]3[/SUP], Lambert SB[SUP]4,[/SUP][SUP]5[/SUP], Nissen M[SUP]5,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Sloots T[SUP]4,[/SUP][SUP]5[/SUP], Booy R[SUP]1,[/SUP][SUP]2,[/SUP][SUP]8,[/SUP][SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIM:[/h] Influenza causes a substantial burden in young children. Vaccine efficacy (VE) data are limited in this age group. We examined trivalent influenza vaccine (TIV) efficacy and safety in young children attending childcare.
[h=4]METHODS:[/h] A double-blind, randomised controlled trial in children aged 6 to <48 months was conducted with recruitment from Sydney childcare centres in 2011. Children were randomised to receive two doses of TIV or control hepatitis A vaccine. Efficacy was evaluated against polymerase chain reaction-confirmed influenza using parent-collected nose/throat swabs during influenza-like-illness. Safety outcomes were assessed during 6 months of follow-up.
[h=4]RESULTS:[/h] Fifty-seven children were allocated to influenza vaccine and 67 to control; all completed the study. The influenza attack rate was 1.8 vs 13.4% in the TIV and control groups, respectively; VE 87% (95%CI: 0-98%). For children aged 24 to <48 months, 0 vs 8 (18.6%) influenza infections occurred in the TIV and control groups respectively, giving a VE of 100% (16-100%). Efficacy was not shown in children 6 to <24 months, probably due to insufficient power. Injection site and systemic adverse events were mostly mild to moderate with no significant differences, apart from more mild diarrhoea following dose 2 in TIV recipients (11.8 vs 0%).
[h=4]CONCLUSIONS:[/h] Influenza vaccine appeared efficacious in the subgroup of children aged 24 to <48 months, although caution is required due to the small number of participants. There were no serious adverse events and most parents would vaccinate again. Influenza vaccination in a childcare setting could be valuable and a larger confirmatory study would be helpful.
? 2016 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
[h=4]KEYWORDS:[/h] childcare; children; influenza; randomised controlled trial; vaccination
PMID: 27592696 DOI: 10.1111/jpc.13313
[PubMed - as supplied by publisher]
[h=1]Influenza vaccine efficacy in young children attending childcare: A randomised controlled trial.[/h] Li-Kim-Moy JP[SUP]1,[/SUP][SUP]2[/SUP], Yin JK[SUP]1,[/SUP][SUP]2[/SUP], Heron L[SUP]1,[/SUP][SUP]2[/SUP], Leask J[SUP]3[/SUP], Lambert SB[SUP]4,[/SUP][SUP]5[/SUP], Nissen M[SUP]5,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Sloots T[SUP]4,[/SUP][SUP]5[/SUP], Booy R[SUP]1,[/SUP][SUP]2,[/SUP][SUP]8,[/SUP][SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIM:[/h] Influenza causes a substantial burden in young children. Vaccine efficacy (VE) data are limited in this age group. We examined trivalent influenza vaccine (TIV) efficacy and safety in young children attending childcare.
[h=4]METHODS:[/h] A double-blind, randomised controlled trial in children aged 6 to <48 months was conducted with recruitment from Sydney childcare centres in 2011. Children were randomised to receive two doses of TIV or control hepatitis A vaccine. Efficacy was evaluated against polymerase chain reaction-confirmed influenza using parent-collected nose/throat swabs during influenza-like-illness. Safety outcomes were assessed during 6 months of follow-up.
[h=4]RESULTS:[/h] Fifty-seven children were allocated to influenza vaccine and 67 to control; all completed the study. The influenza attack rate was 1.8 vs 13.4% in the TIV and control groups, respectively; VE 87% (95%CI: 0-98%). For children aged 24 to <48 months, 0 vs 8 (18.6%) influenza infections occurred in the TIV and control groups respectively, giving a VE of 100% (16-100%). Efficacy was not shown in children 6 to <24 months, probably due to insufficient power. Injection site and systemic adverse events were mostly mild to moderate with no significant differences, apart from more mild diarrhoea following dose 2 in TIV recipients (11.8 vs 0%).
[h=4]CONCLUSIONS:[/h] Influenza vaccine appeared efficacious in the subgroup of children aged 24 to <48 months, although caution is required due to the small number of participants. There were no serious adverse events and most parents would vaccinate again. Influenza vaccination in a childcare setting could be valuable and a larger confirmatory study would be helpful.
? 2016 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
[h=4]KEYWORDS:[/h] childcare; children; influenza; randomised controlled trial; vaccination
PMID: 27592696 DOI: 10.1111/jpc.13313
[PubMed - as supplied by publisher]